Summit Therapeutics

Summit Therapeutics Quick Ratio

The Quick Ratio (Acid Test) of Summit Therapeutics (SMMT) as of Nov 22, 2026 is 10.14. In the previous year, Quick Ratio (Acid Test) was 9.30 — a change of 9.08% (higher).

Quick Ratio

10.14

YoY

9.08%

Last updated:

Quick Ratio (Acid Test) of Summit Therapeutics is 2024 10.14 . Quick Ratio (Acid Test) of Summit Therapeutics was 2023 9.30 . It decreases by 9.08% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics Stock analysis

What does Summit Therapeutics do? Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Summit Therapeutics stock

Quick Ratio (Acid Test) of Summit Therapeutics is 10.14 in 2024.

Quick Ratio (Acid Test) of Summit Therapeutics changed from 9.30 to 10.14, representing a 9.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Summit Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Summit Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Summit Therapeutics

All Key Metrics — Summit Therapeutics